# Personalized Adoptive T-cell Therapy for AML

> **NIH CA R01** · BETH ISRAEL DEACONESS MEDICAL CENTER · 2026 · $728,501

## Abstract

Abstract/Project Summary
The development of strategies to expand and activate AML specific T cells is of critical importance. We have
developed a personalized cancer vaccine in which patient derived tumor cells are fused with autologous
dendritic cells (DCs), presenting a broad array of antigens that capture the heterogeneity of the leukemia cell
population, including shared and neoantigens. We have completed a phase II clinical trial in which patients that
achieve remission following chemotherapy undergo serial vaccination with DC/AML fusions. Remarkably,
despite a median age of 63, 71% remained free of disease with a median follow up of 5 years. Vaccination was
associated with the expansion of T cells targeting both autologous AML cells and leukemia associated
antigens. The DC/AML vaccine can be used as a platform to generate activated leukemia-specific T cells ex-
vivo for adoptive immunotherapy. In this way, effector cells may be generated that are leukemia specific,
capture tumor heterogeneity, and are activated ex vivo to achieve a functionally competent phenotype. We
have demonstrated that vaccine stimulation in the context of IL7/IL-15 results in enhanced levels of central
memory cells critical for long term persistence of response. While the generation of vaccine stimulated
leukemia specific T cells ex vivo represents a promising strategy to effectively target AML cells in vivo, the
immunosuppressive nature of the tumor microenvironment remains a barrier to the development of a memory
response and long-term protection. We performed transcriptome analysis in the remission bone marrow at
time of vaccination to identify biomarkers that were predictive of durable response as compared to early
relapse following vaccination with DC/AML fusions. Of note, decreased expression of TGF-β in the bone
marrow microenvironment was associated with durable remission. These results are consistent with prior
reports suggesting TGF-β as a negative regulator of tumor immunogeni

## Key facts

- **NIH application ID:** 11251612
- **Project number:** 5R01CA262629-05
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **Principal Investigator:** David E. Avigan; Jacalyn  Rosenblatt
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $728,501
- **Award type:** 5
- **Project period:** 2021-07-01T00:00:00 → 2026-12-31T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11251612

## Citation

> US National Institutes of Health, RePORTER application 11251612, Personalized Adoptive T-cell Therapy for AML (5R01CA262629-05). Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/grant/nih/11251612. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*